# CJC-1295 / Ipamorelin: Research Overview — LKN Peptides > A skeptical literature summary of the CJC-1295/ipamorelin combination — a GHRH analog paired with a selective ghrelin-receptor peptide that has never itself been tested in a controlled human trial. A GHRH analog paired with a selective ghrelin-receptor agonist — a combination whose two halves are separately documented and whose combination, as sold, has never been tested together in a controlled human trial. ## The short version CJC-1295/ipamorelin is a two-peptide combination sold together in research-use communities: CJC-1295, the long-acting GHRH analog described on this desk's other page, paired with ipamorelin, a five-amino-acid peptide that activates a separate receptor — the ghrelin receptor (GHS-R1a) — on the same pituitary cells. The pitch is that the two arms, acting through independent pathways, produce a larger GH pulse together than either alone. That combination logic rests on receptor-level cell studies and on each peptide's own separate human data — not on a trial of the fixed blend itself. No controlled human study has tested CJC-1295 and ipamorelin dosed together as sold. This page is explicit about that gap: findings describing 'the stack' are inferences built by stitching together CJC-1295's own six-to-eight-day pharmacodynamics with ipamorelin's separate, much shorter GH pulse — not a demonstrated joint effect. ## What it is This page covers a two-peptide combination sold together in research-use communities: [CJC-1295](/cjc-1295), the long-acting GHRH analog described in full on its own page, paired with ipamorelin, a five-amino-acid peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin receptor, GHS-R1a. Ipamorelin is described in the literature as more receptor-selective than older growth-hormone-releasing peptides, meaning it is reported to avoid meaningfully raising cortisol or prolactin at doses that still stimulate GH release. The combination is sold in both DAC and no-DAC CJC-1295 variants, a distinction that matters for how long any GH elevation from the CJC-1295 half actually lasts. ## How it works CJC-1295 binds the GHRH receptor, raising cAMP through a Gs-protein pathway and driving GH synthesis and release, exactly as described on its own page [4]. Ipamorelin binds a separate receptor, GHS-R1a, on the same pituitary somatotrophs, signaling instead through a Gq-protein pathway that raises intracellular calcium. Because the two pathways are independent, the proposed logic is that stimulating both at once produces a GH pulse larger than either receptor could produce alone. Supporting that logic at the cellular level, a 2002 study using cloned GHRH and ghrelin receptors transfected into HeLa cells found that co-activating both receptors produced roughly double the cAMP response of activating the GHRH receptor by itself [9] — a receptor cross-talk finding, but one measured in an artificial transfected-cell system, not in a pituitary gland or a living animal, and never followed up in CJC-1295/ipamorelin specifically. ## What the research shows No study has tested CJC-1295 and ipamorelin dosed together as a fixed combination in humans. What exists instead is a set of adjacent findings, each with its own scope and limits. A 2026 meta-analysis of five randomized controlled trials examined tesamorelin — a different GHRH analog, not CJC-1295 — in HIV-associated lipodystrophy, finding significant reductions in visceral fat and hepatic fat, increased lean mass and IGF-1, and no serious adverse events [6]. This is offered here only as read-across context for what GHRH-receptor stimulation generally does in a controlled human trial; it is not data on CJC-1295 or on this combination. A 2018 review of GH secretagogues as a drug class found them generally well tolerated, with increased blood glucose from reduced insulin sensitivity as the chief safety concern, and flagged that long-term cancer-incidence and mortality data are still needed [7] — again, class-level evidence, not combination-specific evidence. CJC-1295's own single-agent pharmacodynamics — GH elevated for six or more days, IGF-1 for nine to eleven days after one dose [4] — are described in full on its [own page](/cjc-1295). The DAC linker chemistry that gives CJC-1295 its long duration was characterized in rats, where it produced roughly a four-fold increase in the area under the GH curve compared to unmodified hGRF(1-29), with albumin-bound peptide still detectable in plasma beyond 72 hours [8] — an animal pharmacology study, not a human one. Finally, the receptor cross-talk work described above, in transfected HeLa cells, is the only direct evidence for the 'two receptors are better than one' logic behind the combination [9]. Every one of these five sources describes something real and citable. None of them is a trial of the actual combination as sold and used. ## Reported effects, cautions & safety What follows on user-reported effects is anecdotal, not clinical evidence, drawn from peptide-user forums, clinic blogs, and consumer peptide guides describing the combination as taken outside any clinical trial. *Reported benefits:* Deeper, more restorative sleep is the most-cited effect, often noticed within the first one to two weeks of a pre-bed protocol. Frequently reported: faster workout recovery and less soreness, often grouped with other recovery-focused peptides in community write-ups, and a noticeable uptick in appetite in the hours after dosing (the ghrelin-receptor arm's expected signature, welcome for those trying to eat more, unwanted for those cutting). Reported occasionally: gradual fat loss and a leaner look over five-plus weeks (almost always alongside deliberate diet and training changes), firmer skin, faster-growing nails and hair, and improved mood or daytime energy — the latter usually attributed to better sleep rather than a direct effect. *Reported adverse effects:* Injection-site redness, itching, or mild swelling is the most consistently mentioned complaint. Reported occasionally: transient water retention or puffiness in the fingers, ankles, or face (milder than reports for older GH-releasing peptides); a brief facial flush or head-rush in the minutes after injecting, often compared to a niacin flush; tingling or mild carpal-tunnel-like hand symptoms, tied to the same fluid-shift mechanism discussed on the CJC-1295 page; grogginess or a 'spacey' feeling after dosing; and brief lightheadedness or dizziness shortly after injecting. *Cited cautions:* - **Theoretical proliferation risk from sustained GH/IGF-1 elevation.** CJC-1295 alone raises GH two- to ten-fold and IGF-1 one-and-a-half- to three-fold for over a week after a single dose [4], and combining it with a GH-releasing peptide is intended to amplify the pulse further; because IGF-1 is a known proliferative signal, this is a mechanism-based concern for anyone with a personal or family history of cancer or an undiagnosed tumor — it has not been tested for carcinogenicity as a blend. - **Reduced insulin sensitivity and higher blood sugar.** A review of GH secretagogues found the class generally well tolerated but flagged increased blood glucose and decreased insulin sensitivity as the chief metabolic concern [7] — the predictable risk of a combination built specifically to raise GH output, and least predictable in people who already have impaired glucose handling. - **The blend itself is untested, and its two halves run on different clocks.** No controlled trial has evaluated CJC-1295 and ipamorelin dosed together. CJC-1295 with DAC covalently binds albumin and produces GH and IGF-1 elevation lasting six to eight days [4][8], while ipamorelin produces a single short pulse cleared within hours; pairing a multi-day agent with a short-acting one means the net GH exposure of any specific protocol is not characterized. - **Fluid retention, carpal tunnel, and joint pain.** These are classic markers of GH excess, and a GH-secretagogue review lists them among the class's tolerability considerations [7], consistent with CJC-1295's own documented GH/IGF-1 elevation [4]. - **No long-term safety data, and unverified research-grade material.** Neither peptide is regulator-approved, the blend has no human trial behind it, and the same secretagogue review that frames the class as generally well tolerated still says long-term, large-population safety data are lacking [7]; research-grade peptide from unregulated suppliers also carries no pharmaceutical-grade guarantee of identity, purity, or sterility. - **Cardiovascular and fluid-overload vulnerability.** GH-driven sodium and water retention can worsen edema-prone states, a consideration the secretagogue review lists among sustained-GH-elevation concerns [7], compounded by CJC-1295's multi-day GH signal [4]. ## Where it fits in the GH axis The CJC-1295/ipamorelin combination is the two-receptor step on this desk: it keeps [CJC-1295](/cjc-1295)'s GHRH-receptor arm and adds ipamorelin's ghrelin-receptor arm on top, with in-vitro cell work suggesting the two pathways potentiate rather than simply add. What it does not have — and what CJC-1295 alone also lacks — is a controlled human trial of the combination as actually sold and used. [MOTS-c](/mots-c) sits outside this pituitary-receptor logic entirely. See the [comparison page](/compare) for how the evidence quality differs across all three. ![CJC-1295/Ipamorelin research illustration — abstract endocrine-signaling motifs in obsidian blue](/images/cjc1295-ipamorelin.webp) --- This is a skeptic's literature desk, not a clinic or a peptide supplier — every claim here is bounded by exactly the evidence that was actually measured.